Literature DB >> 5069220

Cephalexin levels in human bile in presence of biliary tract disease.

J E Sales, M Sutcliffe, F O'Grady.   

Abstract

Cephalexin was given to 24 patients before and after operation on the bile ducts and gall bladder. Two patients had obstructive jaundice. Samples of the bile were taken either directly from the gall bladder at operation or via the T-tube. Cephalexin was excreted in the bile, peak levels being obtained after two to three hours. These levels could be raised if probenecid was given concurrently. Higher levels were found in patients with functioning gall-bladders. A trial of cephalexin seems justified for the treatment of typhoid carriers.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5069220      PMCID: PMC1786031          DOI: 10.1136/bmj.3.5824.441

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  7 in total

1.  AMPICILLIN THERAPY OF SALMONELLA CARRIERS: A SUMMARY OF LABORATORY AND CLINICAL OBSERVATIONS.

Authors:  W E BULLOCK
Journal:  Am J Med Sci       Date:  1963-07       Impact factor: 2.378

2.  Factors influencing the cure of Salmonella carriers.

Authors:  B S TYNES; J P UTZ
Journal:  Ann Intern Med       Date:  1962-12       Impact factor: 25.391

3.  The excretion and concentration of aureomycin in the abnormal human biliary tract.

Authors:  J ZASLOW; T H HEWLETT; R W LORRY
Journal:  Gastroenterology       Date:  1950-10       Impact factor: 22.682

4.  Cephalexin: in vitro bacterial susceptibility, absorption in volunteers, and antibacterial activity of sera and urine.

Authors:  R L Perkins; H N Carlisle; S Saslaw
Journal:  Am J Med Sci       Date:  1968-08       Impact factor: 2.378

5.  Biliary excretion of antibiotics in man.

Authors:  G Acocella; R Mattiussi; F B Nicolis; R Pallanza; L T Tenconi
Journal:  Gut       Date:  1968-10       Impact factor: 23.059

6.  Ampicillin levels in human bile in the presence of biliary tract disease.

Authors:  P R Mortimer; D B Mackie; S Haynes
Journal:  Br Med J       Date:  1969-07-12

7.  Cephalexin, a new orally absorbed cephalosporin antibiotic.

Authors:  W E Wick
Journal:  Appl Microbiol       Date:  1967-07
  7 in total
  10 in total

1.  Micro-organisms in the bile. A preventable cause of sepsis after biliary surgery.

Authors:  M R Keighley
Journal:  Ann R Coll Surg Engl       Date:  1977-07       Impact factor: 1.891

2.  Biliary excretion of moxalactam.

Authors:  O V Martinez; J U Levi; A Livingstone; T I Malinin; R Zeppa; D Hutson; N Einhorn
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

Review 3.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

4.  Biliary levels of ceforanide.

Authors:  D E Kenady; M D Ram
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

5.  [The liver concentration of cephradin and cephacetril and their elimination in the bile].

Authors:  D Maroske; H Knothe; A Rox
Journal:  Infection       Date:  1976       Impact factor: 3.553

Review 6.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

7.  Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile.

Authors:  K R Ratzan; H B Baker; I Lauredo
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

8.  Experimental studies of biliary excretion of piperacillin.

Authors:  P Calhoun; K B Brown; R Strunk; D A Krusch; W M Scheld; J B Hanks
Journal:  Ann Surg       Date:  1987-04       Impact factor: 12.969

9.  [Investigations on the excretion of cefaclor in human bile (author's transl)].

Authors:  O Müller; U Rückert; K Fabricius
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 10.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.